TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

SERB PHARMACEUTICALS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: US

Quick snapshot

SERB PHARMACEUTICALS

ST13

US500000079398397

Class

1, 5, 10, 42, 44

Filing

79398397

Registration

7862495

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

36

Latest update

04/03/2026

Classification

Registered

Trademark type

Combined

Nice classes

1, 5, 10, 42, 44

Filing date

01/15/2024

Registration date

07/15/2025

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

07/15/2025

Last transaction

04/03/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

3

Owner type

99

Owner location

LU

Examiner

DOMBROW, COLLEEN M

Law office

L10

Current location

FILE REPOSITORY (FRANCONIA)

Mark description

The mark consists of the wording "SERB PHARMACEUTICALS". The word "SERB" appears above the word "PHARMACEUTICALS". To the left of the wording is a circular shape resembling a donut.

Holders and representatives

Holders

SERB

Representatives

Sherry L. Rollo Hahn Loeser & Parks, LLP

Technical classification

Nice Classes

Class 1Class 5Class 10Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

Chemical preparations for scientific use, other than for medical or veterinary use; Chemical substances for scientific use for analyses in laboratories, other than for medical or veterinary use; chemical preparations and substances with or without coloring agents for laboratory analyses, other than for medical or veterinary use; chemical preparations for scientific purposes other than for medical or veterinary use; diagnostic preparations and substances in the nature of chemicals with or without coloring agents other than for medical or veterinary use, namely, chemical diagnostic reagents for industrial purposes; chemical additives with or without coloring agents used in the composition of diagnostic preparations and substances, namely, chemical additives for use in the manufacture of pharmaceuticals; chemical reagents with or without coloring agents, other than for medical or veterinary use, namely, chemical reagents for non-medical purposes; active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of snake bite venom, the treatment of digoxin toxicity and overdose, the treatment of methotrexate toxicity and overdose, the treatment of exposure to nuclear radiation and the treatment of cyanide poisoning.

Class 5

Pharmaceutical preparations, medicines and substances, namely, pharmaceutical preparations for treating poisonings, overdoses of any type, allergies, snake bites, exposure to nuclear radiations, infections, tumors, heart diseases, blood diseases, skin diseases, gastric diseases, liver diseases, neurological diseases, ophthalmological diseases, lung diseases, rheumatological diseases, rare ocular diseases; Pharmaceutical preparations for the treatment of snake bite venom; Pharmaceutical preparations for the treatment of digoxin toxicity and overdose; Pharmaceutical preparations for the treatment of methotrexate toxicity and overdose; Pharmaceutical preparations, namely, potassium iodide, for the treatment of exposure to nuclear radiation; Pharmaceutical preparations for the treatment of cyanide poisoning; Antidotes; veterinary preparations, medicines and substances, namely, veterinary preparations of snake bite venom to treat snake bites, veterinary preparations for the treatment of digoxin toxicity and overdose, veterinary preparations for the treatment of methotrexate toxicity and overdose, veterinary preparations for the treatment of cyanide poisoning; Biological preparations for medical, pharmaceutical and veterinary use, namely, biological preparations for the treatment of cancer; radioactive substances for medical use; dietetic beverages and foods adapted for medical use; nutritional supplements for medical use; diagnostic preparations for medical or veterinary use; chemical reagents for medical or veterinary use; radiological contrast substances for medical use; herbal tinctures for medical use; surgical implants made of living tissue; medical and veterinary microbial media, namely, cell culture media for medical and veterinary use; cultures of microorganisms for medical or veterinary use; antibiotic preparations; dressings for medical use.

Class 10

Surgical apparatus and instruments for medical, dental and veterinary use; infusion apparatus for therapeutic use; thermometers for medical use; Artificial implants, namely, implants consisting of artificial materials; stents; Dental prostheses; cardiac pacemakers; lenses in the nature of intraocular prostheses for surgical implantation; Orthopedic articles, namely, orthopedic braces for the prevention and the correction of disorders of the musculoskeletal system affecting bones, joints, muscles, tendons and nerves; x-ray apparatus for medical use; Electromagnetic medical diagnostic imaging apparatus; Medical diagnostic instruments for the analysis of body fluids; Medical diagnostic equipment, namely, diagnostic penlights for medical purposes

Class 42

Medical research services; Scientific research for medical use; pharmaceutical diagnostic testing services, namely, testing of pharmaceuticals; pharmaceutical diagnostic testing services, namely, scientific research in the nature of conducting clinical trials for others in the field of pharmaceuticals; Research and development of new products; assessment in scientific and technical fields provided by engineers, namely, consulting in the field of engineering; Appraisals in the fields of science and technology provided by engineers, namely, conducting scientific feasibility studies; scientific research; Technical and scientific studies, namely, conducting scientific feasibility studies

Class 44

Medical services; medical assistance; veterinary services; consultation with respect to pharmacy, namely, pharmaceutical consultation.

Publications

History of USPTO decisions and trademark events.

36 publications found

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

02/26/2026

FICS

FINAL DISPOSITION NOTICE SENT TO IB

02/06/2026

FIMP

FINAL DISPOSITION PROCESSED

02/06/2026

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

12/11/2025

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

11/26/2025

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

11/26/2025

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/15/2025

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

07/15/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

07/15/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/27/2025

PUBO

PUBLISHED FOR OPPOSITION

05/27/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

05/21/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/29/2025

XAEC

EXAMINER'S AMENDMENT ENTERED

04/29/2025

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

04/29/2025

GNEA

EXAMINERS AMENDMENT E-MAILED

04/29/2025

CNEA

EXAMINERS AMENDMENT -WRITTEN

04/29/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

04/24/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/24/2025

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

04/24/2025

NREP

NEW REPRESENTATIVE AT IB RECEIVED

01/23/2025

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

01/03/2025

GNFR

FINAL REFUSAL E-MAILED

01/03/2025

CNFR

FINAL REFUSAL WRITTEN

01/03/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

12/30/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/30/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

12/30/2024

RFNT

REFUSAL PROCESSED BY IB

09/09/2024

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

08/20/2024

RFRR

REFUSAL PROCESSED BY MPU

08/20/2024

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

08/13/2024

CNRT

NON-FINAL ACTION WRITTEN

08/12/2024

DOCK

ASSIGNED TO EXAMINER

08/09/2024

MAFR

APPLICATION FILING RECEIPT MAILED

07/01/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/01/2024

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

06/27/2024

Continuous trademark protection

Get notified about every new filing that threatens SERB PHARMACEUTICALS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.